Key takeaways

• Ocrevus (ocrelizumab) targets CD20 to quickly deplete circulating B cells, a driver of inflammatory activity in MS.
• After B-cell depletion, downstream shifts occur in the T-cell compartment, including reduced pro‑inflammatory signatures and changes in regulatory balance.
• These immune changes align with clinical benefits seen with ocrelizumab in relapsing and primary progressive MS.
• Monitoring B-cell counts and immunoglobulins helps guide safety and timing around vaccinations and infection risk.

MS and the B–T cell interplay

Multiple sclerosis (MS) is an immune-mediated disease in which the body’s defenses target components of the central nervous system, damaging myelin and the cells that produce it. While T cells long held center stage as the main culprits, a wealth of research has repositioned B cells as key coordinators of MS pathology. They present antigens, shape T-cell behavior through co-stimulatory molecules, and secrete cytokines that either inflame or calm the immune response. Because B and T cells cross‑talk constantly, changing one side of the equation often rebalances the other.

How Ocrevus works

Ocrevus (ocrelizumab) is a humanized monoclonal antibody that binds CD20 on pre‑B and mature B cells, sparing stem cells and most plasma cells. By tagging these B cells for destruction (primarily via antibody‑dependent cellular cytotoxicity and complement), ocrelizumab:

• Removes antigen-presenting B cells that activate pro‑inflammatory T cells.
• Reduces secretion of inflammatory cytokines from B cells.
• Disrupts B–T cell synapses that sustain chronic immune activation within the CNS and periphery.

Clinically, this mechanism is associated with fewer relapses, fewer new MRI lesions, and slower disability progression compared with placebo or interferon in relapsing MS, and with slowed disability accumulation in primary progressive MS.

What happens first: rapid B-cell depletion

After the initial split dose of ocrelizumab (two 300 mg infusions two weeks apart), circulating CD19+/CD20+ B cells typically plummet to very low or undetectable levels within about two weeks. This swift depletion reduces the supply of B cells that can present antigen and amplify T-cell–mediated inflammation. B-cell reconstitution is gradual and variable across individuals, generally beginning months after treatment and often remaining below baseline through standard six‑month dosing intervals.

What follows: downstream alterations in T cells

With B cells out of the picture, T cells lose a key source of activation signals and inflammatory cues. Over subsequent weeks to months, multiple T-cell shifts are commonly observed:

• Reduced pro‑inflammatory tone:
  • Lower activity in T helper 1 (Th1) and T helper 17 (Th17) pathways that are associated with MS relapses and lesion formation.
  • Diminished expression of activation markers on T cells that would otherwise be sustained by B-cell co‑stimulation.
• Regulatory recalibration:
  • Signals consistent with improved regulatory balance, including patterns associated with regulatory T cells (Tregs), are reported in some studies.
  • Altered cytokine milieu (for example, less IL‑6 and GM‑CSF from B cells) can indirectly promote a less inflammatory T‑cell phenotype.
• Targeting of CD20+ T cells:
  • A small subset of T cells expresses low levels of CD20; these cells can also be depleted by ocrelizumab, potentially contributing to reduced T‑cell–driven inflammation.
• Functional and repertoire effects:
  • Changes in T-cell trafficking and repertoire diversity may occur as the chronic B–T activation loop is interrupted.

Taken together, the sequence is often: rapid B-cell depletion, then progressive rebalancing of T-cell phenotypes away from aggressive, lesion‑forming behavior and toward a more regulated state.

Clinical implications of the two-step immune effect

• Relapse control: Fast B-cell depletion aligns with early reductions in new inflammatory MRI lesions and relapses.
• Progression: Over months, the T-cell recalibration may help limit smoldering inflammation that contributes to disability accumulation.
• Dosing cadence: Standard maintenance dosing every six months aims to sustain B-cell suppression and the downstream T-cell benefits.

Monitoring and biomarkers

While practices vary by clinic and region, common elements include:

• Peripheral B-cell counts (CD19+ or CD20+) to confirm depletion and track repopulation dynamics.
• Serum immunoglobulins (especially IgG) to evaluate infection risk during long‑term therapy.
• General labs (CBC, liver function) to monitor overall safety.
• Optional disease activity markers (e.g., neurofilament light chain) when available to complement MRI and clinical assessments.

Vaccination and infection considerations

• Live vaccines are generally avoided during treatment and for a period after, due to impaired immune responses.
• Inactivated vaccines can be given, but responses may be blunted. Many clinics schedule vaccinations several weeks before an infusion or in the mid‑cycle window to optimize response.
• Long‑term therapy can lower immunoglobulins in some people; clinicians may adapt monitoring or preventive strategies accordingly.

What patients may notice

• Infusion schedule: Initial split dose (two infusions two weeks apart), then one infusion every six months.
• Early effects: Many patients experience quick suppression of MRI activity; symptom changes vary by individual.
• Common side effects: Infusion‑related reactions (e.g., rash, throat irritation, flushing) are usually mild to moderate and managed with premedication and slowed infusion rates.

Open questions and ongoing research

• Which immune signatures best predict who will respond most robustly to B-cell depletion?
• How do different repopulation patterns of B cells relate to relapse risk or progression?
• Can individualized dosing based on B-cell kinetics maintain efficacy while minimizing hypogammaglobulinemia?
• What is the long‑term impact of ocrelizumab on CNS‑resident immune cells and compartmentalized inflammation behind a closed blood–brain barrier?